Prasad – Talk Bio

FDA Seeks Greater Alignment Between CBER and CDER: Makary Informs Industry Leaders

3 weeks ago talkbio0Tagged Biological Factors, CBER, CDER, Cells, Drug Industry, gene therapy, George Tidmarsh, Makary, Marty, Prasad, regulatory harmonization, United States Food and Drug Administration

FDA; CBER; CDER; regulatory harmonization; Marty Makary; George Tidmarsh; Vinay Prasad; cell and gene therapy; biologics; pharmaceutical industry

Vinay Prasad Departs FDA Amid Conservative Criticism and Sarepta Gene Therapy Controversy

3 weeks ago talkbio0Tagged CBER, conservative criticism, departure - ActRelationshipType, Drug Approval, gene therapy, Muscular Dystrophy, Duchenne, Prasad, Transplant Registry Unified Management Program, United States Food and Drug Administration, Vinay

Vinay Prasad; FDA; departure; Sarepta Therapeutics; gene therapy; Duchenne muscular dystrophy; conservative criticism; CBER; drug approval controversy; Trump administration

Vinay Prasad’s First Major Policy: Challenging Covid Vaccine ‘Dogma’ at FDA

3 months ago talkbio0Tagged Clinical Trials, COVID19 (disease), Policy, Prasad, public health medicine (field), Recommendation, Regulatory Framework, United States Food and Drug Administration, Vaccines, Vinay

Vinay Prasad; FDA; Covid-19 vaccines; policy change; clinical trials; vaccine recommendations; public health; regulatory framework

Vinay Prasads FDA Appointment Anything but Status Quo

4 months ago talkbio0Tagged Anything, Appointments, Prasad, Prasad 's, Status Quo, United States Food and Drug Administration, Vaccines

United States Food and Drug Administration, Appointments, Vaccines, Prasad, Prasad ‘s, Anything, Status Quo

Biotech stocks plunge and industry figures left to wonder after Prasad’s FDA appointment

4 months ago talkbio0Tagged Appointments, Cell Therapy, figures, Industry, Market, Prasad, stocks, United States Food and Drug Administration

United States Food and Drug Administration, Industry, Prasad, Appointments, stocks, Cell Therapy, Market, figures